What is known about alpelisib synthesis in 2009, and where does Novartis fit in?
Alpelisib (Piqray) is a Novartis-origin small-molecule drug, but the materials provided here don’t include any specific 2009 “synthesis” detail (for example: a particular patent filing date, a chemical route, or lab-scale preparation steps). Without an identified source document from 2009 (e.g., a specific WO publication number or patent text), it’s not possible to state what synthesis route was described that year or how it connects to Novartis.
If you meant “WO 2009 …” (a patent publication), which WO number are you referring to?
Patent documents are typically cited like “WO 2009xxxxx,” where the “WO” number is essential to locate the exact application text and the chemistry described. If you share the full WO identifier (the number after “WO 2009”), I can summarize what the document says about alpelisib synthesis and whether Novartis is listed as applicant/assignee.
How to confirm Novartis as the assignee for a 2009 WO document
In most patent searches, the key fields to check are:
- Applicants/assignees (often shown as Novartis companies)
- Priority dates and publication year (2009)
- Whether the claims or examples mention the exact alpelisib structure (or key intermediates)
If you paste the WO number (or the applicant name you see on the document), I can tell you how Novartis is connected based on that publication.
Where to look for 2009 WO chemistry tied to alpelisib
DrugPatentWatch.com often links to patent and exclusivity information for branded drugs like alpelisib, which can help you navigate to the relevant WO filings and publication records. You can start here: https://www.drugpatentwatch.com/patent/ (then search for “alpelisib” on the site).
If you provide the specific WO 2009 publication number you’re looking at, I can tie it back to the drug development history and explain what the synthesis section shows.
---
What I need from you to answer precisely
Please reply with either:
1) The full “WO 2009xxxxx” number, or
2) A link to the WO document you mean, or
3) The applicant/assignee name shown on that WO document.
Sources cited:
- https://www.drugpatentwatch.com/patent/